Labetuzumab govitecan

N/A

Report date: 2024/02/05 13:55:55

Base Information

Drug NameLabetuzumab govitecan
Drug Alias Nameanti-CEACAM5-SN-38hMN-14-SN38IMMU-130
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > CL2A linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > SN-38 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 antagonistsDNA topoisomerase I inhibitors
TargetsCarcinoembryonic antigen related cell adhesion molecule 5DNA topoisomerase I
Therapy Area/IndicationsRectal NeoplasmsColonic NeoplasmsColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesImmunomedicsIbc Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences Inc
Active IndicationsN/A
Inactive IndicationsRectal NeoplasmsColonic NeoplasmsColorectal Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A